Retatrutide Phase 3: what TRIUMPH-1 found

What just happened

The TRIUMPH program is Eli Lilly's Phase 3 trial package for retatrutide — the GLP-1/GIP/glucagon triple agonist that first made headlines in a 2023 Phase 2 trial showing 24.2% weight loss in 338 adults. Phase 2 was striking. Phase 3 is what the FDA actually reviews.

TRIUMPH-4 reported in December 2025: 28.7% weight loss at 68 weeks in a cohort with osteoarthritis alongside obesity. TRIUMPH-1, announced May 21, 2026, is the pivotal trial — 2,339 adults, the largest retatrutide study ever run. Mean weight loss of 28.3% at 80 weeks. For the BMI ≥35 subgroup who continued to 104 weeks: 30.3%.

The 30.3% figure puts retatrutide in the same range as Roux-en-Y gastric bypass, which produces roughly 30–35% total body weight loss. The drug is doing that without surgery.

Retatrutide weight loss numbers in context

To understand why 28–30% matters, you need the comparison numbers. Semaglutide's pivotal STEP 1 trial showed 14.9% weight loss at 68 weeks. Tirzepatide's SURMOUNT-1 showed 20.9% at 72 weeks on the highest dose. Retatrutide is adding roughly 7–10 percentage points on top of what the current best approved drug produces.

That is not a marginal improvement. At 200 lbs starting weight, the difference between 20.9% and 28.3% is 15 lbs. At 300 lbs, it is 22 lbs. The gap compounds with body size. The mechanism behind the gap is the glucagon receptor — it raises resting energy expenditure directly in the liver, something semaglutide and tirzepatide cannot do.

Beyond weight: retatrutide hits multiple systems

The osteoarthritis finding in TRIUMPH-4 is worth stopping on. A 75.8% reduction in osteoarthritis pain at 68 weeks. That is not purely the result of weighing less — it is a clinically meaningful outcome for a population that often cannot exercise because joint pain stops them first. A drug that clears the pain barrier to movement, while driving weight loss simultaneously, changes the intervention sequence.

Other secondary outcomes: roughly 20% drop in LDL cholesterol, 72% reversal rate of prediabetes to normoglycemia, and the 86% liver fat reduction documented in the 2024 Phase 2 substudy. The metabolic profile is broad. These are not small effects on secondary markers — they are outcomes that change cardiovascular risk trajectories.

The safety signal

Every good-news headline from TRIUMPH needs this footnote: GI adverse events are more common with retatrutide than with tirzepatide or semaglutide. Nausea, vomiting, and diarrhea rates are higher. Not catastrophically so — but measurably higher.

What does not appear in the data: unexpected organ-level toxicity, cardiac signals beyond the mild heart rate elevation seen in Phase 2, or anything that would obviously derail FDA review. But tolerability matters in practice. A 30% weight loss trajectory means nothing if a significant fraction of patients stop taking the drug in month three.

Lilly has not released granular discontinuation-due-to-adverse-events numbers for TRIUMPH-1 yet. That data will matter for how prescribers position retatrutide against tirzepatide once both are available. It also matters for insurance coverage decisions.

Where retatrutide stands now

Lilly has maintained NDA submission guidance for Q4 2026 since early in the year. TRIUMPH-1 completing gives them the data package they need. Whether they hit that timeline depends on the remaining TRIUMPH trials that have not yet reported. Seven Phase 3 trials are expected to read out during 2026.

Researchers are also studying retatrutide for effects beyond obesity — including addiction-related behaviors that GLP-1 agonists appear to modulate through dopaminergic circuits. That work is separate from the weight loss indication and significantly earlier-stage.

What to do with this information today

If you are already on tirzepatide or semaglutide, TRIUMPH-1 does not change your immediate calculus. Retatrutide is not available. It will not be for at least 18 months under the most optimistic scenario. What is available — tirzepatide — produces clinically significant weight loss and is FDA-approved today.

If you are considering starting a GLP-1 drug and wondering whether to wait: the math does not favor it. Eighteen months of untreated obesity carries real metabolic cost. Starting tirzepatide now and switching when retatrutide launches is a realistic option once approval happens. Check the best GLP-1 programs for what is actually accessible today.

What TRIUMPH-1 changes is the ceiling. We now know how far this drug class can go. The answer is further than most expected — and the data keeps improving.